The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Methadone‐Related Opioid Agonist Pharmacotherapy for Heroin Addiction: History, Recent Molecular and Neurochemical Research and Future in Mainstream Medicine
Abstract
A bstract:In 1963, Professor Vincent P. Dole at the Rockefeller University formed a small team to develop a pharmacotherapy for the management of heroin addiction. They hypothesized that heroin addiction is a disease of the brain with behavioral manifestations, and not merely a personality disorder or criminal behavior and began to address the specific question of whether a long‐acting opioid agonist could be used in the long‐term maintenance treatment of heroin addiction. Over the next 35 years, many studies documented the safety, efficacy and effectiveness of methadone pharmacotherapy for heroin addiction, but Federal regulations and stigmatization of heroin addiction prevented implementation of treatment. Finally, in 1999, NIH published a report unequivocally supporting methadone maintenance pharmacotherapy for heroin addiction. Two other effective opioid agonist treatments have been developed: the even longer acting opioid agonist l‐alpha‐acetylmethadol (LAAM) has been approved for pharmacotherapy for heroin addiction, and still under study is the opioid partial agonist‐antagonist buprenorphine‐naloxone combination. A variety of studies, both laboratory based and clinical, have revealed the mechanisms of action of long‐acting opioid agonists in treatment, including prevention of disruption of molecular, cellular and physiologic events and, in fact, allowing normalization of those functions disrupted by chronic heroin use. Recent molecular biological studies have revealed single nucleotide polymorphisms of the human μ opioid receptor gene; the m opioid receptor is the site of action of heroin, the major opiate drug of abuse, analgesic agents such as morphine, and the major treatment agents for heroin addiction. These findings support the early hypotheses of our laboratory that addiction may be due to a combination of genetic, drug‐induced and environmental (including behavioral) factors and also, that atypical stress responsivity may contribute to the acquisition and persistence of, as well as relapse to, use of addictive drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Opiate Receptor: Demonstration in Nervous Tissue
Pert, C. B., & Snyder, S. H. (1973) · Science · doi:10.1126/science.179.4077.1011 · Cited by 2,388
Bond, C., LaForge, K. S., Tian, M., Melia, D., Zhang, S., Borg, L., Gong, J., Schluger, J., Strong, J. A., Leal, S. M., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9608 · Cited by 1,074
Self-citationStereospecific Binding of the Potent Narcotic Analgesic [ 3 H]Etorphine to Rat-Brain Homogenate
Simon, E. J., Hiller, J. M., & Edelman, I. (1973) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.70.7.1947 · Cited by 1,067
Tsuang, M. T., Lyons, M. J., Meyer, J. M., Doyle, T., Eisen, S. A., Goldberg, J., True, W., Lin, N., Toomey, R., & Eaves, L. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.11.967 · Cited by 710
Drug dependence: stress and dysregulation of brain reward pathways
Kreek, M. J., & Koob, G. F. (1998) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00064-7 · Cited by 696
Self-citationTerenius, L. (1973) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1973.tb01477.x · Cited by 659
Effective Medical Treatment of Opiate Addiction
Addiction, N. C. D. P. O. E. M. T. O. O. (1998) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.280.22.1936 · Cited by 577
Goldstein, A., Lowney, L. I., & Pal, B. K. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.8.1742 · Cited by 419
HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987
Jarlais, D. C. D. (1989) · JAMA · doi:10.1001/jama.261.7.1008 · Cited by 323
DOLE, V. P. (1966) · Archives of Internal Medicine · doi:10.1001/archinte.1966.00290160004002 · Cited by 290
Cited by
Opioid Abuse in Chronic Pain — Misconceptions and Mitigation Strategies
Volkow, N. D., & McLellan, A. T. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1507771 · Cited by 1,305
Stress dysregulation of drug reward pathways, and the transition to drug dependence
Koob, & Kreek, M. J. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.05030503 · Cited by 868
Self-citationThe neurobiology of opioid dependence: implications for treatment
Kosten, T., & George, T. (2002) · Science & Practice Perspectives · doi:10.1151/spp021113 · Cited by 505
Kakko, J., Svanborg, K. D., Kreek, M. J., & Heilig, M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12600-1 · Cited by 466
Self-citationKreek, M. J., LaForge, K. S., & Butelman, E. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd897 · Cited by 374
Self-citation
Metadata
- Authors
- KREEK, M. J.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2000-01
- Volume
- 909
- Issue
- 1
- Pages
- 186-216
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W2069642322
- Cited by
- 258
- References
- 85
- FWCI
- 10.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Methadone‐Related Opioid Agonist Pharmacotherapy for Heroin Addiction: History, Recent Molecular and Neurochemical Research and Future in Mainstream Medicine. https://app.cochat.ai/papers/10.1111/j.1749-6632.2000.tb06683.x
- The paper
- KREEK, M. J. (2000). Methadone‐Related Opioid Agonist Pharmacotherapy for Heroin Addiction: History, Recent Molecular and Neurochemical Research and Future in Mainstream Medicine. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.2000.tb06683.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.